Cellectis to Cut 70% of Staff in Gene Therapy Pivot
Cellectis to Cut 70% of Staff in Gene Therapy Pivot
Cellectis to Cut 70% of Staff in Gene Therapy Pivot
Key points
اہم نکات
मुख्य बातें
- Paris-based biotech Cellectis will cut up to 70% of its workforce as it pivots from CAR-T cancer therapies to in vivo gene editing, the company disclosed in its third-quarter results on Friday.
- The firm entered 2026 with 229 full-time staff across Paris, New York and Raleigh, North Carolina, and scrapped its two clinical-stage CAR-T programs in September.
- It is now focused on two preclinical candidates, HEAL-101 and HEAL-201, with first trial data expected in 2027 and 2028.
- Paris-based biotech Cellectis will cut up to 70% of its workforce as it pivots from CAR-T cancer therapies to in vivo gene editing, the company disclosed in its third-quarter results on Friday.
- The firm entered 2026 with 229 full-time staff across Paris, New York and Raleigh, North Carolina, and scrapped its two clinical-stage CAR-T programs in September.
- It is now focused on two preclinical candidates, HEAL-101 and HEAL-201, with first trial data expected in 2027 and 2028.
- Paris-based biotech Cellectis will cut up to 70% of its workforce as it pivots from CAR-T cancer therapies to in vivo gene editing, the company disclosed in its third-quarter results on Friday.
- The firm entered 2026 with 229 full-time staff across Paris, New York and Raleigh, North Carolina, and scrapped its two clinical-stage CAR-T programs in September.
- It is now focused on two preclinical candidates, HEAL-101 and HEAL-201, with first trial data expected in 2027 and 2028.
Paris-based biotech Cellectis will cut up to 70% of its workforce as it pivots from CAR-T cancer therapies to in vivo gene editing, the company disclosed in its third-quarter results on Friday. The firm entered 2026 with 229 full-time staff across Paris, New York and Raleigh, North Carolina, and scrapped its two clinical-stage CAR-T programs in September. It is now focused on two preclinical candidates, HEAL-101 and HEAL-201, with first trial data expected in 2027 and 2028. The cuts, spread over 2026 and 2027, are meant to stretch its $149 million cash pile into the second half of 2028.
Paris-based biotech Cellectis will cut up to 70% of its workforce as it pivots from CAR-T cancer therapies to in vivo gene editing, the company disclosed in its third-quarter results on Friday. The firm entered 2026 with 229 full-time staff across Paris, New York and Raleigh, North Carolina, and scrapped its two clinical-stage CAR-T programs in September. It is now focused on two preclinical candidates, HEAL-101 and HEAL-201, with first trial data expected in 2027 and 2028. The cuts, spread over 2026 and 2027, are meant to stretch its $149 million cash pile into the second half of 2028.
Paris-based biotech Cellectis will cut up to 70% of its workforce as it pivots from CAR-T cancer therapies to in vivo gene editing, the company disclosed in its third-quarter results on Friday. The firm entered 2026 with 229 full-time staff across Paris, New York and Raleigh, North Carolina, and scrapped its two clinical-stage CAR-T programs in September. It is now focused on two preclinical candidates, HEAL-101 and HEAL-201, with first trial data expected in 2027 and 2028. The cuts, spread over 2026 and 2027, are meant to stretch its $149 million cash pile into the second half of 2028.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।